Glucotrack Stock Analysis
| GCTK Stock | USD 4.92 0.28 5.38% |
GlucoTrack is overvalued with Real Value of 4.72 and Hype Value of 4.9. The main objective of GlucoTrack stock analysis is to determine its intrinsic value, which is an estimate of what GlucoTrack is worth, separate from its market price. There are two main types of GlucoTrack's stock analysis: fundamental analysis and technical analysis.
The GlucoTrack stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA.
GlucoTrack | Build AI portfolio with GlucoTrack Stock |
GlucoTrack Stock Analysis Notes
The company has price-to-book (P/B) ratio of 0.69. Some equities with similar Price to Book (P/B) outperform the market in the long run. GlucoTrack recorded a loss per share of 1268.49. The entity had not issued any dividends in recent years. The firm had 1:60 split on the 16th of June 2025. GlucoTrack, Inc., a medical device company, designs, develops, and commercializes non-invasive glucose monitoring devices for use by people suffering from diabetes and pre-diabetics in Israel and internationally. GlucoTrack, Inc. was founded in 2001 and is based in Or Yehuda, Israel. Glucotrack operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 5 people. To learn more about GlucoTrack call the company at 201 842 7715 or check out https://glucotrack.com.GlucoTrack Investment Alerts
| GlucoTrack is way too risky over 90 days horizon | |
| GlucoTrack appears to be risky and price may revert if volatility continues | |
| GlucoTrack has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (22.6 M) with loss before overhead, payroll, taxes, and interest of (20 K). | |
| GlucoTrack currently holds about 3.85 M in cash with (12.49 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.25. | |
| GlucoTrack has a poor financial position based on the latest SEC disclosures | |
| Latest headline from seekingalpha.com: Glucotrack GAAP EPS of -4.64 |
GlucoTrack Upcoming and Recent Events
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
GlucoTrack Environmental, Social, and Governance (ESG) Scores
GlucoTrack's ESG score is a quantitative measure that evaluates GlucoTrack's performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of GlucoTrack's operations that may have significant financial implications and affect GlucoTrack's stock price as well as guide investors towards more socially responsible investments.
GlucoTrack Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Xtx Topco Ltd | 2025-06-30 | 0.0 | Hrt Financial Llc | 2025-06-30 | 0.0 | Bank Of America Corp | 2025-06-30 | 4.1 K | Tower Research Capital Llc | 2025-06-30 | 1.8 K | Barclays Plc | 2025-06-30 | 751 | Newbridge Financial Services Group, Inc. | 2025-06-30 | 34.0 | Fmr Inc | 2025-06-30 | 21.0 | Sbi Securities Co Ltd | 2025-06-30 | 10.0 | Ubs Group Ag | 2025-06-30 | 1.0 | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 1.0 | Advisor Group Holdings, Inc. | 2025-06-30 | 1.0 |
GlucoTrack Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 4.48 M.GlucoTrack Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 3.81 | 4.00 | |
| Return On Capital Employed | (3.12) | (2.97) | |
| Return On Assets | 3.81 | 4.00 | |
| Return On Equity | (1.74) | (1.65) |
Management Efficiency
GlucoTrack has return on total asset (ROA) of (2.2566) % which means that it has lost $2.2566 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (14.9095) %, meaning that it created substantial loss on money invested by shareholders. GlucoTrack's management efficiency ratios could be used to measure how well GlucoTrack manages its routine affairs as well as how well it operates its assets and liabilities. At this time, GlucoTrack's Return On Tangible Assets are quite stable compared to the past year. Return On Assets is expected to rise to 4.00 this year, although the value of Return On Capital Employed is projected to rise to (2.97). At this time, GlucoTrack's Total Current Liabilities is quite stable compared to the past year. Non Current Liabilities Total is expected to rise to about 18.5 M this year, although the value of Liabilities And Stockholders Equity will most likely fall to about 4 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (34.95) | (36.70) | |
| Tangible Book Value Per Share | (34.95) | (36.70) | |
| Enterprise Value Over EBITDA | (7.33) | (7.70) | |
| Price Book Value Ratio | (12.81) | (12.16) | |
| Enterprise Value Multiple | (7.33) | (7.70) | |
| Price Fair Value | (12.81) | (12.16) |
Understanding the operational decisions made by GlucoTrack management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Technical Drivers
As of the 20th of November, GlucoTrack retains the Risk Adjusted Performance of 0.0359, market risk adjusted performance of 0.9217, and Downside Deviation of 7.09. GlucoTrack technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.GlucoTrack Price Movement Analysis
java.lang.NullPointerException: Cannot invoke "java.lang.Number.intValue()" because the return value of "sun.invoke.util.ValueConversions.primitiveConversion(sun.invoke.util.Wrapper, Object, boolean)" is null. The output start index for this execution was zero with a total number of output elements of zero. The Triple Exponential Moving Average (T3) indicator is developed by Tim Tillson as GlucoTrack price series composite of a single exponential moving average, a double exponential moving average and a triple exponential moving average.
GlucoTrack Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific GlucoTrack insiders, such as employees or executives, is commonly permitted as long as it does not rely on GlucoTrack's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases GlucoTrack insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
GlucoTrack Outstanding Bonds
GlucoTrack issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. GlucoTrack uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most GlucoTrack bonds can be classified according to their maturity, which is the date when GlucoTrack has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
GlucoTrack Predictive Daily Indicators
GlucoTrack intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of GlucoTrack stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
GlucoTrack Forecast Models
GlucoTrack's time-series forecasting models are one of many GlucoTrack's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary GlucoTrack's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About GlucoTrack Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how GlucoTrack prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling GlucoTrack shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as GlucoTrack. By using and applying GlucoTrack Stock analysis, traders can create a robust methodology for identifying GlucoTrack entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (19.37) | (20.34) | |
| Operating Profit Margin | 15.11 | 14.36 | |
| Net Loss | (19.37) | (20.34) | |
| Gross Profit Margin | 0.87 | 0.91 |
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding GlucoTrack to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Stocks Directory Now
Stocks DirectoryFind actively traded stocks across global markets |
| All Next | Launch Module |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlucoTrack. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. For more information on how to buy GlucoTrack Stock please use our How to buy in GlucoTrack Stock guide.You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlucoTrack. If investors know GlucoTrack will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlucoTrack listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of GlucoTrack is measured differently than its book value, which is the value of GlucoTrack that is recorded on the company's balance sheet. Investors also form their own opinion of GlucoTrack's value that differs from its market value or its book value, called intrinsic value, which is GlucoTrack's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlucoTrack's market value can be influenced by many factors that don't directly affect GlucoTrack's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlucoTrack's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlucoTrack is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlucoTrack's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.